Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Polymeric gene delivery of ischemia-inducible VEGF significantly attenuates infarct size and apoptosis following myocardial infarct

Gene Therapy volume 16, pages 127–135 (2009)Cite this article

Abstract

The development of clinically beneficial myocardial gene therapy has been slowed by reliance on the use of viral carriers and non-physiologic, constitutive gene expression. To specifically address these issues, we have developed a non-viral gene carrier, water-soluble lipopolymer (WSLP), and an ischemia-inducible plasmid construct expressing vascular endothelial growth factor (VEGF), pRTP801-VEGF, to treat myocardial ischemia and infarction. Rabbits underwent ligation of the circumflex artery followed by injection of (a) an ischemia-inducible VEGF gene construct in a WSLP carrier; (b) a constitutively expressed, or unregulated, SV-VEGF gene construct in a WSLP carrier; (c) WSLP carrier alone; or (d) no injection therapy. Following 4 weeks treatment, ligation alone resulted in infarction of 48±7% of the left ventricle. With injection of WSLP carrier alone, 49±6% of the left ventricle was infarcted (P=NS). The constitutively expressed gene construct, SV-VEGF, reduced the infarct size to 32±7% of the left ventricle (P=0.007). The ischemia-inducible gene construct, RTP801-VEGF, further reduced the infarct size to 13±4% of the left ventricle (P<0.001). The use of a non-viral carrier to deliver an ischemia-inducible VEGF construct is effective in the treatment of acutely ischemic myocardium.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Lee LY, Patel SR, Hackett NR, Mack CA, Polce DR, El-Sawy T et al. Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. Ann Thorac Surg 2000; 69: 14–23; discussion 23–24.

    Article  CAS  Google Scholar 

  2. Nakamura T, Mizuno S, Matsumoto K, Sawa Y, Matsuda H, Nakamura T . Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 2000; 106: 1511–1519.

    Article  CAS  Google Scholar 

  3. Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999; 100: 468–474.

    Article  CAS  Google Scholar 

  4. Symes JF, Losordo DW, Vale PR, Lathi KG, Esakof DD, Mayskiy M et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 1999; 68: 830–836; discussion 836–837.

    Article  CAS  Google Scholar 

  5. Goncalves LM . Angiogenic growth factors: potential new treatment for acute myocardial infarction? Cardiovasc Res 2000; 45: 294–302.

    Article  CAS  Google Scholar 

  6. Hao X, Mansson-Broberg A, Grinnemo KH, Siddiqui AJ, Dellgren G, Brodin LA et al. Myocardial angiogenesis after plasmid or adenoviral VEGF-A(165) gene transfer in rat myocardial infarction model. Cardiovasc Res 2007; 73: 481–487.

    Article  CAS  Google Scholar 

  7. Ruixing Y, Jiaquan L, Jie C, Dezhai Y . Intravenous administration of vascular endothelial growth factor improves cardiac performance and inhibits cardiomyocyte apoptosis. Growth Factors 2006; 24: 209–217.

    Article  Google Scholar 

  8. Luo Z, Diaco M, Murohara T, Ferrara N, Isner JM, Symes JF . Vascular endothelial growth factor attenuates myocardial ischemia–reperfusion injury. Ann Thorac Surg 2007; 64: 993–998.

    Article  Google Scholar 

  9. Spyridopoulos I, Brogi E, Kearney M, Sullivan AB, Cetrulo C, Isner JM et al. Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-alpha: balance between growth and death signals. J Mol Cell Cardiol 1997; 29: 1321–1330.

    Article  CAS  Google Scholar 

  10. Giordano FJ, Gerber HP, Williams SP, VanBruggen N, Bunting S, Ruiz-Lozano P et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci USA 2001; 98: 5780–5785.

    Article  CAS  Google Scholar 

  11. Yoon YS, Uchida S, Masuo O, Cejna M, Park JS, Gwon HC et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation 2005; 111: 2073–2085.

    Article  CAS  Google Scholar 

  12. Bull DA, Bailey SH, Rentz JJ, Zebrack JS, Lee M, Litwin SE et al. Effect of Terplex/VEGF-165 gene therapy on left ventricular function and structure following myocardial infarction. VEGF gene therapy for myocardial infarction. J Control Release 2003; 93: 175–181.

    Article  CAS  Google Scholar 

  13. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD . Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001; 7: 425–429.

    Article  CAS  Google Scholar 

  14. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM . VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000; 102: 898–901.

    Article  CAS  Google Scholar 

  15. Schwarz ER, Speakman MT, Patterson M, Hale SS, Isner JM, Kedes LH et al. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat—angiogenesis and angioma formation. J Am Coll Cardiol 2000; 35: 1323–1330.

    Article  CAS  Google Scholar 

  16. Lee M, Bikram M, Oh S, Bull DA, Kim SW . Sp1-dependent regulation of the RTP801 promoter and its application to hypoxia-inducible VEGF plasmid for ischemic disease. Pharm Res 2004; 21: 736–741.

    Article  CAS  Google Scholar 

  17. Crottogini A, Meckert P, Vera Janavel G, Lascano E, Negroni J, Del Valle H et al. Arteriogenesis induced by intramyocardial vascular endothelial growth factor 165 gene transfer in chronically ischemic pigs. Hum Gene Ther 2003; 14: 1307–1318.

    Article  CAS  Google Scholar 

  18. Laguens R, Cabeza Meckert P, Vera Janavel G, De Lorenzi A, Lascano E, Negroni J et al. Cardiomyocyte hyperplasia after plasmid-mediated vascular endothelial growth factor gene transfer in pigs with chronic myocardial ischemia. Gene Med 2004; 6: 222–227.

    Article  CAS  Google Scholar 

  19. Vera Janavel G, Crottogini A, Cabeza Meckert P, Cuniberti L, Mele A, Papouchado M et al. Plasmid-mediated VEGF gene transfer induces cardiomyogenesis and reduces myocardial infarct size in sheep. Gene Therapy 2006; 13: 1133–1142.

    Article  CAS  Google Scholar 

  20. Zygalaki E, Kaklamanis L, Nikolaou NI, Kyrzopoulos S, Houri M, Kyriakides Z et al. Expression profile of total VEGF, VEGF slice variants and VEGF receptors in the myocardium and arterial vasculature of diabetic and non-diabetic patients with coronary artery disease. Clin Biochem 2008; 41: 82–87.

    Article  CAS  Google Scholar 

  21. Sasso F, Torella D, Carbonara O, Ellison G, Torella M, Scardone M et al. Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease. J Am Coll Cardiol 2005; 46: 827–834.

    Article  CAS  Google Scholar 

  22. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604–4613.

    Article  CAS  Google Scholar 

  23. Levy AP, Levy NS, Wegner S, Goldberg MA . Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995; 270: 13333–13340.

    Article  CAS  Google Scholar 

  24. Liu Y, Cox SR, Morita T, Kourembanas S . Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res 1995; 77: 638–643.

    Article  CAS  Google Scholar 

  25. Dibbens JA, Miller DL, Damert A, Risau W, Vadas MA, Goodall GJ . Hypoxic regulation of vascular endothelial growth factor mRNA stability requires the cooperation of multiple RNA elements. Mol Biol Cell 1999; 10: 907–919.

    Article  CAS  Google Scholar 

  26. Lee M, Choi D, Choi MJ, Jeong JH, Kim WJ, Oh S et al. Hypoxia-inducible gene expression system using the erythropoietin enhancer and 3′-untranslated region for the VEGF gene therapy. J Control Release 2006; 115: 113–119.

    Article  CAS  Google Scholar 

  27. Stein I, Neeman M, Shweiki D, Itin A, Keshet E . Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol Cell Biol 1995; 15: 5363–5368.

    Article  CAS  Google Scholar 

  28. Nakagawa K, Chen YX, Ishibashi H, Yonemitsu Y, Murata T, Hata Y et al. Angiogenesis and its regulation: roles of vascular endothelial cell growth factor. Semin Thromb Hemost 2000; 26: 61–66.

    Article  CAS  Google Scholar 

  29. Tang MX, Szoka FC . The influence of polymer structure on the interactions of cationic polymers with DNA and morphology of the resulting complexes. Gene Therapy 1997; 4: 823–832.

    Article  CAS  Google Scholar 

  30. Rabinowitz JE, Samulski J . Adeno-associated virus expression systems for gene transfer. Curr Opin Biotechnol 1998; 9: 470–475.

    Article  CAS  Google Scholar 

  31. Robbins PD, Ghivizzani SC . Viral vectors for gene therapy. Pharmacol Ther 1998; 80: 35–47.

    Article  CAS  Google Scholar 

  32. Abdallah B, Goula D, Ghorbel M, Guissouma H, Benoist C, Seugnet I et al. Nonviral gene transfer for studying signaling in comparative developmental biology. Ann N Y Acad Sci 1998; 839: 87–92.

    Article  CAS  Google Scholar 

  33. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415–419.

    Article  CAS  Google Scholar 

  34. Hollon T . Researchers and regulators reflect on first gene therapy death. Nat Med 2000; 6: 6.

    Article  CAS  Google Scholar 

  35. Nakamura T, Mizuno S, Matsumoto K, Sawa Y, Matsuda H, Nakamura T . Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 2000; 106: 1511–1519.

    Article  CAS  Google Scholar 

  36. Harvey BG, Hackett NR, El-Sawy T, Rosengart TK, Hirschowitz EA, Lieberman MD et al. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J Virol 2000; 73: 6729–6742.

    Google Scholar 

  37. SoRelle R . Shaking the world of gene therapy. Circulation 2000; 101: E9052–E9053.

    CAS  PubMed  Google Scholar 

  38. Cristiano RJ, Roth JA . Molecular conjugates: a targeted gene delivery vector for molecular medicine. J Mol Med 1995; 73: 479–486.

    Article  CAS  Google Scholar 

  39. Felgner P, Zelphati O, Liang X . Advances in Synthetic Gene-Delivery System, the Development of Human Gene Therapy. Cold Spring Harbor Laboratory Press: New York, 2000.

    Google Scholar 

  40. Godbey WT, Wu KK, Mikos AG . Size matters: molecular weight affects the efficiency of poly(ethylenimine) as a gene delivery vehicle. J Biomed Mater Res 1999; 45: 268–275.

    Article  CAS  Google Scholar 

  41. Gao X, Huang L . A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem Biophys Res Commun 1999; 179: 280–285.

    Article  Google Scholar 

  42. Gill DR, Southern KW, Mofford KA, Seddon T, Huang L, Sorgi F et al. A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Therapy 1997; 4: 199–209.

    Article  CAS  Google Scholar 

  43. Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X et al. Direct gene transfer with DNA–liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993; 90: 11307–11311.

    Article  CAS  Google Scholar 

  44. Lee M, Rentz J, Bikram M, Han SO, Bull DA, Kim SW . Hypoxia-inducible VEGF gene delivery to ischemic myocardium using water-soluble lipopolymer. Gene Ther 2003; 10: 1535–1542.

    Article  CAS  Google Scholar 

  45. Lee M, Rentz J, Han SO, Bull DA, Kim SW . Water-soluble lipopolymer as an efficient carrier for gene delivery to myocardium. Gene Therapy 2003; 10: 585–593.

    Article  CAS  Google Scholar 

  46. Janat-Amsbury MM, Yockman JW, Lee M, Kern S, Furgeson DY, Bikram M et al. Combination of local, nonviral IL12 gene therapy and systemic paclitaxel treatment in a metastatic breast cancer model. Mol Ther 2004; 9: 829–836.

    Article  CAS  Google Scholar 

  47. Lee M, Ryu JK, Oh SM, Lee E, Shin HY, Song SU et al. Water-soluble lipopolymer as a gene carrier to corpus cavernosum. Int J Impot Res 2007; 17: 326–334.

    Article  Google Scholar 

  48. Yockman JW, Kim WJ, Chang CW, Kim SW . Non-viral delivery of interleukin-2 and soluble Flk-1 inhibits metastatic and primary tumor growth in renal cell carcinoma. Gene Therapy 2007; 14: 1399–1405.

    Article  CAS  Google Scholar 

  49. Yockman JW, Maheshwari A, Han SO, Kim SW . Tumor regression by repeated intratumoral delivery of water-soluble lipopolymers/p2CMVmIL-12 complexes. J Control Release 2003; 87: 177–186.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by NIH Grants HL071541 (DAB) and HL65477 (SWK).

Author information

Authors and Affiliations

  1. Department of Pharmaceutics and Pharmaceutical Chemistry, Center for Controlled Chemical Delivery, University of Utah Health Sciences Center, Salt Lake City, UT, USA

    J W Yockman, C W Chang & S W Kim

  2. Department of Cardiology, Yonsei Cardiovascular Center, Yonsei University College of Medicine, Seoul, Korea

    D Choi

  3. Division of Cardiothoracic Surgery, Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, UT, USA

    M G Whitten, A Kastenmeier, H Erickson, A Albanil & D A Bull

  4. Deparment of Engineering, College of Bioengineering, Hanyang University, Seoul, Korea

    M Lee

Authors
  1. J W Yockman
    View author publications

    Search author on:PubMed Google Scholar

  2. D Choi
    View author publications

    Search author on:PubMed Google Scholar

  3. M G Whitten
    View author publications

    Search author on:PubMed Google Scholar

  4. C W Chang
    View author publications

    Search author on:PubMed Google Scholar

  5. A Kastenmeier
    View author publications

    Search author on:PubMed Google Scholar

  6. H Erickson
    View author publications

    Search author on:PubMed Google Scholar

  7. A Albanil
    View author publications

    Search author on:PubMed Google Scholar

  8. M Lee
    View author publications

    Search author on:PubMed Google Scholar

  9. S W Kim
    View author publications

    Search author on:PubMed Google Scholar

  10. D A Bull
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to D A Bull.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yockman, J., Choi, D., Whitten, M. et al. Polymeric gene delivery of ischemia-inducible VEGF significantly attenuates infarct size and apoptosis following myocardial infarct. Gene Ther 16, 127–135 (2009). https://doi.org/10.1038/gt.2008.146

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/gt.2008.146

Keywords

This article is cited by

Search

Advanced search

Quick links